- Soto-Perez-de-Celis, Enrique;
- Dale, William;
- Katheria, Vani;
- Kim, Heeyoung;
- Fakih, Marwan;
- Chung, Vincent;
- Lim, Dean;
- Mortimer, Joanne;
- Cabrera Chien, Leana;
- Charles, Kemeberly;
- Roberts, Elsa;
- Vazquez, Jessica;
- Moreno, Jeanine;
- Lee, Ty;
- Fernandes Dos Santos Hughes, Simone;
- Sedrak, Mina;
- Sun, Can-Lan;
- Li, Daneng
INTRODUCTION: Older adults with cancer facing competing treatments must prioritize between various outcomes. This study assessed health outcome prioritization among older adults with cancer starting chemotherapy. METHODS: Secondary analysis of a randomized trial addressing vulnerabilities in older adults with cancer. Patients completed three validated outcome prioritization tools: 1) Health Outcomes Tool: prioritizes outcomes (survival, independence, symptoms) using a visual analog scale; 2) Now vs. Later Tool: rates the importance of quality of life at three times-today versus 1 or 5 years in the future; and 3) Attitude Scale: rates agreement with outcome-related statements. The authors measured the proportion of patients prioritizing various outcomes and evaluated their characteristics. RESULTS: A total of 219 patients (median [range] age 71 [65-88], 68% with metastatic disease) were included. On the Health Outcomes Tool, 60.7% prioritized survival over other outcomes. Having localized disease was associated with choosing survival as top priority. On the Now vs. Later Tool, 50% gave equal importance to current versus future quality of life. On the Attitude Scale, 53.4% disagreed with the statement the most important thing to me is living as long as I can, no matter what my quality of life is; and 82.2% agreed with the statement it is more important to me to maintain my thinking ability than to live as long as possible. CONCLUSION: Although survival was the top priority for most participants, some older individuals with cancer prioritize other outcomes, such as cognition and function. Clinicians should elicit patient-defined priorities and include them in decision-making.